What is BNTX stock price today?

BNTX (Biontech Se) stock is trading at $110.23 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is BNTX stock going up or down today?

BNTX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy BNTX stock now?

The decision to buy BNTX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is BNTX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for BNTX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is BNTX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if BNTX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is BNTX's P/E ratio?

P/E ratio data for BNTX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is BNTX's market cap?

BNTX (Biontech Se) has a market capitalization of $27.66 billion, making it a mid-cap stock.

What is BNTX's price to book ratio?

BNTX trades at a price-to-book (P/B) ratio of 1.27, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does BNTX pay dividends?

BNTX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is BNTX's dividend yield?

BNTX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is BNTX stock a good long-term investment?

BNTX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is BNTX's revenue growth rate?

BNTX has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

BNTX is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in BNTX?

Key risks for BNTX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does BNTX compare to its competitors?

Compare BNTX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize BNTX's performance and positioning.

What is BNTX's stock price target for 2026?

Our AI model provides price targets for BNTX based on fundamental analysis: Bull case $143.30 (+30%), Base case $126.76 (+15%), Bear case $99.21 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about BNTX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for BNTX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is BNTX's next earnings report?

BNTX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

BNTX - Biontech Se

NYSE * Health Care * Biotechnology

$110.23

+$1.43 (+1.31%)

About Biontech Se

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BNTX Key Statistics

Market Cap

$27.66B

P/B Ratio

1.27

EPS

$-2.82

Revenue Growth

+0.2%

Profit Margin

-0.2%

Employees

6,772

How BNTX Compares to Peers

BNTX has the fastest revenue growth among competitors

BNTX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
BNTX(This stock)	$27.66B	N/A	0%	-0.2%	-
AMGNAmgen Inc	$209.24B	27.2	0%	0.2%	vs AMGN
GILDGilead Sciences	$184.91B	22.0	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$126.19B	32.5	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$82.64B	18.8	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.15B	21.8	-0%	0.1%	vs BIIB

Biontech Se Company Information

Headquarters: Germany
Website: www.biontech.de
Sector: Health Care
Industry: Biotechnology

About Biontech Se

BNTX Key Statistics

How BNTX Compares to Peers

Biontech Se Company Information

Upcoming Events for BNTX